Humanized antibodies directed against complement protein C5
US9133269B2 · kind B2 · utility
16Cited by
2References
34Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 21, 2013 |
| Grant date | Sep 15, 2015 |
| Priority date | — |
| Expiry date | Aug 21, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that binds to complement protein C5. The invention provides a C5-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention provides an isolated complement protein C5 epitope. The invention also provides related vectors, compositions, and methods of using the C5-binding agent to treat an C5-mediated disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.